Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of NK211 in ovarian cancer
jRCT2080220963Phase 1
- Sponsor
- Nippon Kayaku Co., Ltd.
- Start
- Jan 2010
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NK211 in ovarian cancer, sponsored by Nippon Kayaku Co., Ltd.
02
Drugs
NK211
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on jRCT2080220963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220963.